The Early Postoperative Morbidity of Transurethral Resection of the Prostate and oF 4 Minimally Invasive Treatment Alternatives
Abstract
Purpose:
We compared the early postoperative morbidity of transurethral resection of the prostate to minimally invasive treatment alternatives with respect to the objective rate of complications and subjective morbidity assessed by a patients addressed diary-type questionnaire.
Materials and Methods:
Parameters evaluated preoperatively were the International Prostate Symptom Score (I-PSS), free flow study, post-void residual, transrectal ultrasonography and a pressure-flow study. The patients underwent transurethral resection reference 28, transrectal high intensity focused ultrasound reference 20, visual laser ablation reference 15, transurethral needle ablation reference 15 and transurethral electrosurgical vaporization reference 17 of the prostate. One the day of hospital discharge the patients received the questionnaire and were asked to answer daily 7 questions concerning micturition status. After 6 weeks the questionnaire was returned and an I-PSS, uroflowmetry and post-void residual were obtained.
Results:
Preoperatively, there was no statistically significant difference regarding the I-PSS, peak flow rate, prostate volume and degree of bladder outlet obstruction. After 6 weeks the peak flow rate improved most prominently after transurethral electrosurgical vaporization (+13.2 ml. per second), transurethral resection of the prostate (+12.3 ml. per second) and visual laser ablation (+11.1 ml. per second). The I-PSS decreased most significantly after transurethral resection (−14.1) and transurethral electrosurgical vaporization (−8.4). There was no difference regarding the rate of adverse events within the first 6 weeks postoperatively in the 5 treatment arms. Mean duration of catheter drainage plus or minus standard deviation was 3.7 +/− 1.2 days after transurethral resection of the prostate, 6.8 +/− 1.7 days after high intensity focused ultrasound, 7.8 +/− 1.5 days after visual laser ablation, 2.0 +/− 0.4 days after transurethral needle ablation and 3.3 +/− 0.8 days after transurethral electrosurgical vaporization. Analysis of the questionnaire revealed that the daytime frequency, degree of hematuria and incontinence were comparable for all 5 procedures within the first 6 weeks postoperatively. Postoperative dysuria was greatest after visual laser ablation and transurethral electrosurgical vaporization. Regarding the degree of nocturia, there was no improvement after visual laser ablation, while the remaining 4 procedures yielded a significant and comparable decrease. The most significant subjective improvement in uroflowmetry was reported after transurethral resection of the prostate and transurethral electrosurgical vaporization. Regarding the global quality of life question, the patients were generally more worried after visual laser ablation and transurethral needle ablation compared to the other 3 procedures.
Conclusions:
The overall morbidity of transurethral resection of the prostate within the first 6 weeks postoperatively is equivalent to that of the 4 minimally invasive treatment alternatives evaluated in our study. When comparing the 4 minimally invasive procedures, no dramatic differences were notable, although visual laser ablation seems to be associated with a greater degree of morbidity as assessed by this questionnaire.
References
- 1 : Benign prostatic hyperplasia. Medical and minimally invasive treatment options.. New Engl. J. Med.1995; 332: 99. Google Scholar
- 2 : Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia.. New Engl. J. Med.1989; 320: 1120. Google Scholar
- 3 : A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia.. Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. New Engl. J. Med.1995; 332: 75. Google Scholar
- 4 : Transurethral prostatectomy: mortality and morbidity.. Prostate1996; 28: 195. Google Scholar
- 5 : Comparative study of laser versus electrocautery prostatic resection: 18-month followup with complex urodynamic assessment.. J. Urol.1995; 153: 94. Abstract, Google Scholar
- 6 : A comparison of transurethral prostatectomy with visual laser ablation of the prostate using the Urolase right-angle fiber for the treatment of BPH.. World J. Urol.1995; 13: 126. Google Scholar
- 7 : Electrovaporisation of the prostate.. Curr. Opin. Urol.1996; 6: 2. Google Scholar
- 8 : Benign prostatic hyperplasia-are we too "hot" on new therapies.. J. Urol.1996; 156: 426. Abstract, Google Scholar
- 9 : Age related urodynamic changes in patients with benign prostatic hyperplasia.. J. Urol.1996; 156: 1662. Abstract, Google Scholar
- 10 : Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple.. World J. Urol.1995; 13: 47. Google Scholar
- 11 : Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound.. J. Urol.1994; 152: 1956. Abstract, Google Scholar
- 12 : Transurethral needle ablation of the prostate: a new treatment of benign prostatic hyperplasia using interstitial low-level radiofrequency energy.. Curr. Opin. Urol.1995; 5: 35. Google Scholar
- 13 : Laser prostatectomy: free beam and contact techniques.. Curr. Opin. Urol.1996; 6: 10. Google Scholar
- 14 : The quality of life during intravesical bacillus Calmette-Guerin therapy.. J. Urol.1996; 155: 1221. Abstract, Google Scholar
- 15 : Transurethral electrovaporization of the prostate with the Vaportrode VE-B.. Preliminary results. Eur. Urol.1996; 29: 450. Google Scholar
- 16 : Urolase laser prostatectomy in patients on warfarin anticoagulation: a safe treatment alternative for bladder outlet obstruction.. Urology1993; 42: 738. Google Scholar
- 17 : Interstitial laser coagulation (ILC) of the prostate in the treatment of benign prostatic hyperplasia.. Urologe A1995; 34: 90. Google Scholar
- 18 : Technique and results of interstitial laser coagulation.. World J. Urol.1995; 13: 109. Google Scholar
- 19 : Lasers in the treatment of benign prostatic obstruction: past, present, and future. Eur. Urol.1996; 30: 1. Google Scholar
- 20 : Laser treatment of the prostate using the urolase fiber: the Dutch experience. J. Urol.1996; 156: 420. Abstract, Google Scholar
- 21 : Transurethral needle ablation (TUNA [TM]): an overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia.. Curr. Opin. Urol.1996; 6: 20. Google Scholar
From the Department of Urology, Institute for Medical Statistics, University of Vienna, Vienna, Austria.
